Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of LEO 43204 for Actinic Keratosis
NCT02305888Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Mar 2015
- Primary completion
- Jul 2015
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ingenol disoxate in actinic keratosis (AK) (3 arms), sponsored by LEO Pharma. Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicities Based on Local Skin Reactions at 8 days. Started Mar 2015; status: completed.
02
Drugs
ingenol disoxate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT02305888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305888.